ERBB2 and breast cancer: Notably, EGFR overexpression was mainly observed in triple-negative breast cancer (TNBC), a subtype of breast cancer with estrogen receptor-negative, progestogen receptor-negative, and HER2 negative, accounting for 45-70% of all TNBC patients62.